Biogen (BIIB) stock
NASDAQ
As of the Nov 5, 2026 close (U.S. Eastern)
Events and reference metrics · 1
- Market cap
- $36.1B
- As of Nov 5, 2026
- P/E
- 104.04x
- Trailing twelve months
- P/B
- 1.91x
- Latest reported equity
- P/S
- 3.51x
- Trailing twelve months
- ROE
- 1.8%
- Trailing twelve months
- Dividend yield
- Not available
- Latest fiscal-year dividends
Multiples use the price as of Nov 5, 2026 and may differ from the current price.
- Market cap
- $36.1B
- As of Nov 5, 2026
- P/E
- 104.04x
- Trailing twelve months
- P/B
- 1.91x
- Latest reported equity
- P/S
- 3.51x
- Trailing twelve months
- ROE
- 1.8%
- Trailing twelve months
- Dividend yield
- Not available
- Latest fiscal-year dividends
Multiples use the price as of Nov 5, 2026 and may differ from the current price.
Compares the share price with the company's earnings, net assets and sales. Check trading status and financial notes separately.
Price date for the multiples · Nov 5, 2026 · Financial period · Trailing twelve months
P/E and P/S use the latest four quarters where available · P/B uses the latest equity · Computed in-house by ChickenStock
P/E
104.04x
P/B
1.91x
P/S
3.51x
Earnings and dividend metrics▾
Earnings
EPS
$2.34
Earnings per share
BPS
$127.85
Book value per share
ROE
1.8%
Return on equity
- EPS — what one share earned over the last four quarters. This company earned $2.34 per share.
- BPS — net assets divided by the number of shares. Each share is backed by $127.85 of net assets.
- ROE — how much the company earned on shareholder equity over a year: 1.8%.
ⓘ What are these valuation metrics?▾
P/E = share price ÷ earnings per share (EPS)
P/B = share price ÷ book value per share (BPS)
P/S = share price ÷ sales per share
P/E shows how many times annual earnings per share the price is; not all earnings are paid to shareholders. P/B compares the price with net assets, and P/S with sales.
Higher or lower is not good or bad by itself. Typical levels differ by industry; read P/B alongside ROE and P/S alongside margins.
ChickenStock computes these from SEC financial filings: net income and revenue are summed over the latest four quarters, and equity is the latest reported balance.
A negative P/E means a net loss. Reference information only, not a recommendation to buy or sell.
Latest earnings
SEC filingsJul–Sep 2026(FY2026 Q3)
Revenue increased 10.6% from the same period a year earlier.
Key reported figures come first. Select one to see the same quarter across three years.
Revenue · same quarter, three years
Year-ago quarter $2.54B+10.6%
$2.47B
Jul–Sep '24
$2.54B
Jul–Sep '25
$2.8B
Jul–Sep '26
The next earnings date has not been confirmed yet.
ⓘ Notes on these figures▾
- Results for Jul–Sep 2026 are from the 10-Q submitted to SEC EDGAR on Oct 28, 2026.
- Earnings per share decreased 104.4% from the same quarter a year earlier.
- Revenue increased 10.6% from the same quarter a year earlier.
- Net income decreased 104.5% from the same quarter a year earlier.
Filed Oct 28, 2026 · 10-Q · SEC EDGAR · View original
Reported results are from SEC EDGAR filings. Reference information only, not investment advice.
Insider transactions
Recent Form 4 filings grouped by person, date and transaction type.
- Grogan JaneHead of Research · Oct 30, 2026Shares withheld for taxes345 shares · $87KAvg. price $253.624,408 shares held after
- Grogan JaneHead of Research · Oct 30, 2026Option exercise695 shares · $0Avg. price $04,753 shares held after
- Godbout SeanChief Accounting Officer · Oct 2, 2026Shares withheld for taxes8 shares · $2KAvg. price $219.881,459 shares held after
- Godbout SeanChief Accounting Officer · Oct 2, 2026Option exercise27 shares · $0Avg. price $01,467 shares held after
- Minor LloydDirector · Aug 4, 2026Open-market sale593 shares · $119KAvg. price $200.962,689 shares held after
- Minor LloydDirector · Aug 3, 2026Open-market sale593 shares · $121KAvg. price $203.343,282 shares held after
Only transactions reported on SEC Form 4 are shown. A sale may follow a pre-arranged 10b5-1 plan, and items such as option exercises or shares withheld for taxes are not open-market trades.
Recent SEC filings
40 filingsRecent filing summaries
Newest first by publication date · may differ from the filing date
- AI summary10-QBiogen said it completed the Apellis acquisition on May 14, 2026, paying shareholders $41.00 in cash per share (about $5.3 billion) and granting one contingent value right of up to $4.00 per share. It said it funded the deal with $2.0 billion and the 2026 Term Loan, among other sources.Published Oct 28, 2026 · Filed Oct 28, 2026Read the summary →
- AI summary8-KThe company said total revenue for Q3 2026 rose 11% year over year to $2.8 billion, and Growth Portfolio revenue rose 49% to $1.26 billion. It said the results included the first full quarter contribution from Apellis products.Published Oct 28, 2026 · Filed Oct 28, 2026Read the summary →
- AI summary8-KBiogen said it held its 2026 Annual Meeting of Stockholders on June 9, 2026, where stockholders elected 10 board nominees to one-year terms running until the 2027 annual meeting.Published Oct 2, 2026 · Filed Jun 10, 2026Read the summary →
- Biogen said it completed the Apellis acquisition on May 14, 2026, paying shareholders $41.00 in cash per share (about $5.3 billion) and granting one contingent value right of up to $4.00 per share. It said it funded the deal with $2.0 billion and the 2026 Term Loan, among other sources.Read the full analysis →
- The company said total revenue for Q3 2026 rose 11% year over year to $2.8 billion, and Growth Portfolio revenue rose 49% to $1.26 billion. It said the results included the first full quarter contribution from Apellis products.Read the full analysis →
Filings submitted to the U.S. Securities and Exchange Commission (EDGAR). Dates are SEC filing dates (U.S. Eastern). Form and item names are the official SEC titles. The Earnings and Risk tags come directly from form types and item codes; they are not written by AI. Insider ownership reports (Forms 3, 4 and 5) are excluded.
Company overview
Expand ▾
Biogen (BIIB) stock information
NASDAQ
Biogen (BIIB) is listed on NASDAQ. Its market capitalization is about $36.1B. On trailing-twelve-month earnings the P/E ratio is 104.04, and the P/B ratio is 1.91. Return on equity is 1.8%. These figures are computed in-house from official filings and are reference information only.
Biogen — frequently asked questions
- What is the P/E ratio of Biogen (BIIB)?
- On a trailing-twelve-month basis, BIIB trades at a P/E ratio of 104.04. It is calculated as market capitalization divided by net income attributable to controlling interests, using official filings. Reference information only.
- What is the market capitalization of Biogen?
- BIIB has a market capitalization of about $36.1B. The figure moves with the share price and is refreshed each trading day.
- Is this page investment advice?
- No. Every figure on this page is factual reference information compiled from public filings. It is not investment advice, not a price forecast and not a recommendation to buy or sell. Investment decisions rest with the user.
All metrics, scores, and content provided by ChickenStock are reference information derived from market data. They are not investment advice or a solicitation to trade. Investment decisions and their consequences rest with the user.